PRQR
ProQR Therapeutics NV
NASDAQ · Healthcare · Biotechnology · NL
$1.83
−3.17%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.11
- Revenue estimate
- $4.3M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.10
- EPS estimate
- -$0.13
- Revenue actual
- $10.0M
- Revenue estimate
- $4.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +4.3%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.75
- PT range
- $3.00 – $10
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.13 | -$0.10 | Beat 23.23% | $10.0M |
| May 12, 2026 | -$0.15 | -$0.15 | In line | $2.3M |
| Mar 12, 2026 | -$0.10 | -$0.09 | Beat 13.83% | $5.5M |
| Nov 6, 2025 | -$0.10 | -$0.12 | Miss -20.00% | $3.4M |
| Aug 7, 2025 | -$0.08 | -$0.14 | Miss -75.00% | $4.5M |
| May 8, 2025 | -$0.09 | -$0.11 | Miss -22.22% | $5.0M |
| Mar 13, 2025 | -$0.10 | -$0.10 | In line | $4.5M |
| Nov 7, 2024 | -$0.12 | -$0.11 | Beat 8.33% | $4.2M |
| Aug 8, 2024 | -$0.12 | -$0.03 | Beat 75.00% | $6.8M |
| May 9, 2024 | -$0.12 | -$0.10 | Beat 16.67% | $4.8M |
| Mar 13, 2024 | -$0.08 | -$0.08 | In line | $3.5M |
| Aug 3, 2023 | -$0.12 | -$0.11 | Beat 8.33% | $1.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026